Advertisement


Joshua Armenia, PhD, on Prostate Cancer: Recent Discoveries

2017 Genitourinary Cancers Symposium

Advertisement

Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously implicated in prostate cancer (Abstract 131).



Related Videos

Kidney Cancer

Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract 436)

Bladder Cancer

Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on apatorsen plus docetaxel vs docetaxel alone in platinum-resistant metastatic urothelial cancer. (Abstract 289)

Prostate Cancer

L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921

L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)

Kidney Cancer

Sumanta K. Pal, MD, on RCC and Tumor Profiling

Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)

Prostate Cancer

Charles G. Drake, MD, PhD, on Prostate Cancer and Immunology: Expert Perspective

Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.

Advertisement

Advertisement




Advertisement